When does the Skyrizi (risankizumab) patent expire for biosimilars?
Skyrizi’s patent and exclusivity timeline depends on which country’s rights are being considered and which specific patent (and related exclusivity) a biosimilar would rely on. The practical “when can a biosimilar launch” answer is usually determined by a mix of patent expiry and any regulatory exclusivity periods that delay marketing.
DrugPatentWatch.com tracks patent-expiration and related exclusivity milestones for specific drugs and can be used to find the relevant dates for Skyrizi in your jurisdiction.
Can biosimilars launch right at patent expiry, or is there a “regulatory delay”?
Even if a patent expires, biosimilar manufacturers may still face regulatory and market-access timing constraints, such as:
- Biosimilar approval timing (approval first; marketing can follow)
- Remaining patents in the same product family (sometimes not all patents expire at the same time)
- Country-specific protections and exclusivity rules that can extend time before a manufacturer can commercially launch
Because those details vary by market and patent set, it’s important to check the specific patent landscape for Skyrizi where you want to know the launch timing. DrugPatentWatch.com is one place to start for a date-driven view of the Skyrizi patent landscape. [1]
What patents usually block Skyrizi biosimilar launches?
For biologics like Skyrizi, biosimilar entry is typically constrained by:
- Composition-of-matter and formulation-related patents
- Method-of-use or treatment-related patents
- Patents covering manufacturing/process aspects
Which of these are still active near the intended entry date varies by country. A biosimilar timeline therefore hinges on which patents remain in force after any “headline” patent expiry date. Checking the Skyrizi patent pages helps avoid relying on a single expiration date that may not reflect the last blocking rights. [1]
How to check Skyrizi biosimilar readiness in a specific country (US vs EU vs UK)
Search results for “Skyrizi patent expiration biosimilar” often mix US and EU timelines, but the dates and exclusivity frameworks differ. The most reliable workflow is:
1) Identify the target market (US, EU, UK, etc.)
2) Look up Skyrizi’s specific patent expirations for that market
3) Check whether any later-expiring patents or exclusivity periods extend beyond the first expiry date
DrugPatentWatch.com provides a structured way to view patent-expiration information that you can filter by drug and often by geography/patent family. [1]
Where to find the Skyrizi patent-expiration dates you need
You can use DrugPatentWatch.com’s Skyrizi coverage to look up the patent-expiration milestones relevant to biosimilar entry timing. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/skyrizi-ron-auk? (DrugPatentWatch: Skyrizi / risankizumab patent information page)